AK-PENTOLATE™ Cyclopentolate Hydrochloride Ophthalmic Solution, USP -Sterile

Manufacturer
Rebel Distributors Corp.
Effective date
2010-09-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:12:23

Label at a glance#

ProductAK-PENTOLATE
Active ingredientCyclopentolate Hydrochloride
Label structure13 sections

Indications and uses

Cyclopentolate hydrochloride ophthalmic solution is used to produce mydriasis and cycloplegia.

Dosage and administration

Adults: Instill one or two drops of 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days. Children: Instill one or two drops of 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 1% solution if necessary.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution) is an anticholinergic prepared as a sterile, borate buffered solution for topical ocular use. It is supplied in two strengths.

Chemical name:
2-(Dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate hydrochloride

MW=327.85            C17H25NO3 • HCl

The active ingredient is represented by the structural formula:

Chemical Structure
Chemical Structure

AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution) USP, 1% & 2%

Each mL contains: Active: Cyclopentolate Hydrochloride 10 mg (1%) or 20 mg (2%).

Preservative: Benzalkonium Chloride 0.1 mg (0.01%).

Inactives: Boric Acid, Edetate Disodium, Potassium Chloride (except 2% strength), Sodium Carbonate and/or Hydrochloric Acid may be added to adjust pH (3.0 to 5.5) and Purified Water USP.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Cyclopentolate hydrochloride ophthalmic solution is used to produce mydriasis and cycloplegia.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution) should not be used when untreated narrow-angle glaucoma, or untreated anatomically narrow angles are present, or if the patient is hypersensitive to any component of this preparation.

WARNINGS

WARNINGS SECTION

For topical ophthalmic use only. Not for injection. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. To minimize absorption, use only 1 drop of 0.5% cyclopentolate hydrochloride ophthalmic solution per eye, followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes.

Mydriatics may produce a transient elevation of intraocular pressure.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome and in those predisposed to angle-closure glaucoma.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Do not touch dropper tip to any surface, as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination.

Drug Interactions

DRUG INTERACTIONS SECTION

Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies in animals or humans have not been conducted to evaluate the carcinogenic potential of cyclopentolate.

Pregnancy

PREGNANCY SECTION

Pregnancy Category C

SPL UNCLASSIFIED SECTION

Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes (see WARNINGS).

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Ocular: Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae have been reported. Non-ocular: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in children, especially with 2% concentration. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common. Other manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death.

OVERDOSAGE

OVERDOSAGE SECTION

Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Adults: Instill one or two drops of 1% or 2% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days. Children: Instill one or two drops of 1% or 2% solution in the eye which may be repeated five to ten minutes later by a second application of 1% solution if necessary.

HOW SUPPLIED

HOW SUPPLIED SECTION

AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution, USP) is a sterile ophthalmic solution supplied in white opaque plastic dropper bottles as follows:

AK-PENTOLATE™ (Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1%)
 15 mL NDC 21695-883-15

DO NOT USE IF IMPRINTED SEAL IS BROKEN OR MISSING.

Storage

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep tightly closed.

KEEP OUT OF THE REACH OF CHILDREN.

SPL UNCLASSIFIED SECTION

Akorn
Lake Forest, IL 60045

CP00N

Revised 05/08

Repackaged by:

Rebel Distributors Corp.

Thousand Oaks, CA 91320

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

AK-Pentolate 1%
AK-Pentolate 1%

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1298352AK-Pentolate 1 % Ophthalmic SolutionPSN1
1298066cyclopentolate HCl 1 % Ophthalmic SolutionPSN1
1298352cyclopentolate hydrochloride 10 MG/ML Ophthalmic Solution [AK-Pentolate]SBD1
1298066cyclopentolate hydrochloride 10 MG/ML Ophthalmic SolutionSCD1
1298352AK-Pentolate 1 % Ophthalmic DropsSY1
1298352AK-Pentolate 10 MG/ML Ophthalmic SolutionSY1
1298066cyclopentolate hydrochloride 1 % Ophthalmic SolutionSY1

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9e37788c-b1bf-42ae-aac9-b60601606144Product name820260122
1527ac37-808d-43be-a63e-74e1258dbe46Product name920250219
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
9fcb7a91-de07-4f00-aabf-e4d6fda403d5Product name820230322
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
0ec3537a-6c9b-432a-896c-b9ea8723049aProduct name920200701
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
7916de40-e296-41f0-b811-6d0df1a33e2cProduct name920180627
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
da26936b-2875-4173-812f-99a1f7074052Product name120151215
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
42f3c020-f1b3-89bc-7bdc-e1f10e680485Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
21695-883-152019-09-24C16284748780-1934fe258-4d88-48b1-e053-8cdaa90a720aAK-PENTOLATE™ Cyclopentolate Hydrochloride Ophthalmic Solution, USP -Sterile

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
21695-883-15AK-PENTOLATE15 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS151

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
21695-883AK-PENTOLATE (CYCLOPENTOLATE HYDROCHLORIDE) SOLUTION/ DROPS [REBEL DISTRIBUTORS CORP.]1Legacy NDC, 1 package rows20110722_1d97ba11-5b69-4ba3-9310-fa000183de43.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
21695-883-15ML - Milliliter21695-883980c26d1-7f40-4b22-a9ad-b026277c9efe12012-07-24
17478-100-02ML - Milliliter17478-10003dfa6bc-6389-4d1a-a84f-e216c3968e3512012-07-24
17478-100-12ML - Milliliter17478-100290d9102-0e8b-4322-ad9c-9917263f256312012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Cyclopentolate HydrochlorideACTIVE INGREDIENT736I6971TE1
CyclopentolateACTIVE MOIETYI76F4SHP7J1
Benzalkonium ChlorideINACTIVE INGREDIENTF5UM2KM3W71
Boric AcidINACTIVE INGREDIENTR57ZHV85D41
Edetate DisodiumINACTIVE INGREDIENT7FLD91C86K1
Hydrochloric AcidINACTIVE INGREDIENTQTT17582CB1
Potassium ChlorideINACTIVE INGREDIENT660YQ98I101
Sodium CarbonateINACTIVE INGREDIENT45P3261C7T1
WaterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
21695-88321695-883-15
17478-100

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 6 · 312 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION / PERINEURALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Potassium ChloridePOTASSIUM CHLORIDE660YQ98I10SUSPENSION / ORALNAExact identifier — unii candidate
18 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KSHAMPOO, SUSPENSION / TOPICAL1 %w/wExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRAPERITONEALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSUSPENSION/ DROPS / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Sodium CarbonateSODIUM CARBONATE45P3261C7TTROCHE / ORAL375 mgExact identifier — unii candidate
28 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBCAPSULE / ORAL7 mgExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KPOWDER, FOR SUSPENSION / ORAL285 mgExact identifier — unii candidate
77 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KSUSPENSION / RESPIRATORY (INHALATION)0.01 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KINJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS0.4 mgExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSOLUTION / URETERALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, EMULSION / INTRAVENOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Sodium CarbonateSODIUM CARBONATE45P3261C7TGUM, CHEWING / BUCCAL720 mgExact identifier — unii candidate
28 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Potassium ChloridePOTASSIUM CHLORIDE660YQ98I10SUSPENSION / OPHTHALMIC0.03 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / OPHTHALMIC1 mgExact identifier — unii candidate
24 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSOLUTION / URETHRALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSUSPENSION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Potassium ChloridePOTASSIUM CHLORIDE660YQ98I10POWDER / RESPIRATORY (INHALATION)0.18 mgExact identifier — unii candidate
18 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBEMULSION / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KINJECTION / INTRAVASCULAR0.48 mgExact identifier — unii candidate
77 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KSPRAY / NASAL1 mgExact identifier — unii candidate
77 equally ranked IID candidates
Benzalkonium ChlorideBENZALKONIUM CHLORIDEF5UM2KM3W7GEL / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
24 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSOLUTION / ORAL223 mgExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KSUSPENSION / OPHTHALMIC0.06 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBDROPS / NASAL10 mlExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS0.18 %w/vExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KGEL / VAGINAL5 mgExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBJELLY / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KSYSTEM / TOPICAL126 mgExact identifier — unii candidate
77 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KSOLUTION/ DROPS / OPHTHALMIC0.13 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
Sodium CarbonateSODIUM CARBONATE45P3261C7TINJECTION / INFILTRATIONADJ PHExact identifier — unii candidate
28 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KINJECTION, SUSPENSION / INTRA-ARTICULAR1 mgExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS4.17 mgExact identifier — unii candidate
148 equally ranked IID candidates
Sodium CarbonateSODIUM CARBONATE45P3261C7TSOLUTION / OPHTHALMIC0.01 %w/vExact identifier — unii candidate
28 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KENEMA / RECTAL60 mgExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSUSPENSION / AURICULAR (OTIC)0.04 %w/vExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBTABLET / ORAL2.32 mgExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Boric AcidBORIC ACIDR57ZHV85D4SUSPENSION/ DROPS / OPHTHALMIC22 mgExact identifier — unii candidate
17 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KSOLUTION / NASAL100 mg/100mlExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION / RETROBULBARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / SUBCUTANEOUS2 mgExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSPRAY / NASAL10 mlExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KINJECTION / INTRACARDIAC2 mgExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRACAVITARYADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KGEL / TOPICAL24 mgExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRACAUDALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBAEROSOL, SPRAY / RESPIRATORY (INHALATION)1.5 %w/wExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KTABLET, COATED / ORAL0.21 mgExact identifier — unii candidate
77 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KINJECTION, EMULSION / INTRAVENOUS59 mgExact identifier — unii candidate
77 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KSUSPENSION/ DROPS / AURICULAR (OTIC)0.01 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
Potassium ChloridePOTASSIUM CHLORIDE660YQ98I10INJECTION, SOLUTION / INTRAVENOUS330 mgExact identifier — unii candidate
18 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRALESIONALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
Edetate DisodiumEDETATE DISODIUM7FLD91C86KINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS6 mgExact identifier — unii candidate
77 equally ranked IID candidates
Hydrochloric AcidHYDROCHLORIC ACIDQTT17582CBSUSPENSION / NASALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A040164-001AKPENTOLATECYCLOPENTOLATE HYDROCHLORIDE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A040164-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-1384e616aacf4f…
2026-08-18 06:07:402026-07A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-1331067a03dcf5…
2025-08-23 18:47 UTC2025-08A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-136a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-1303ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-132680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-135bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-1379d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-131e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-138072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-135c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-135d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-134b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-1374a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-1387673890dc5c…
2021-03-12 10:30 UTC2021-03A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-135aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-138869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-133f01610625f2…
2019-09-15 20:21 UTC2019-09A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13b00525d2431f…
2019-07-19 19:46 UTC2019-07A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-136a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-131c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-139b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-133f0d92c62455…
2023-05-13 08:27 UTC2023-05A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13053a50430f4f…
2023-01-26 05:58 UTC2023-01A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-133bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-133a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A040164-001AKPENTOLATE1%SOLUTION/DROPS / OPHTHALMICAT1997-01-13f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A040164-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A040164-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040164-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040164-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A040164-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040164-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040164-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040164-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040164-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040164-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040164-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040164-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040164-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040164-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040164-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040164-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040164-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040164-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040164-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040164-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040164-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040164-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040164-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A040164-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040164-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040164-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040164-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A040164-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A040164-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040164-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040164-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040164-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040164-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040164-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040164-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040164-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A040164-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A040164-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A040164-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A040164-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
1d97ba11-5b69-4ba3-9310-fa000183de431d97ba11-5b69-4ba3-9310-fa000183de432010-09-01Warnings, Adverse reactionsExact identifier
spl id: 1d97ba11-5b69-4ba3-9310-fa000183de43
spl set id: 1d97ba11-5b69-4ba3-9310-fa000183de43

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.